Journal
WORLD JOURNAL OF CLINICAL ONCOLOGY
Volume 5, Issue 4, Pages 560-567Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5306/wjco.v5.i4.560
Keywords
Epidermal growth factor receptor mutation; Tyrosine kinase inhibitor; Lung cancer; Adenocarcinoma; Resistance; Targeted therapy
Categories
Funding
- Genentech
Ask authors/readers for more resources
The identification of driver mutations and drugs that inhibit their activity has been a major therapeutic advance for patients with advanced lung adenocarcinoma. Unfortunately, the success of these drugs is limited by the universal development of resistance. Treatment failure can result from inadequate drug exposure or selection of resistant malignant clones. Clinically distinct mechanisms of disease progression have been identified and can inform treatment decisions. Investigations into the biochemical mechanisms of tyrosine kinase inhibitor resistance may provide additional therapeutic targets by which the efficacy of targeted therapy can be improved. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available